[Form 4] Aura Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aura Biosciences, Inc. (AURA) reported an insider tax-related stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 17,109 shares of common stock at a weighted average price of $5.42 per share, with individual sale prices ranging from $5.42 to $5.44. The filing explains that these shares were sold automatically to cover tax withholding obligations tied to the vesting of restricted stock units, and the transactions were not at the officer’s discretion. After these sales, the reporting person beneficially owned 252,685 shares of Aura Biosciences common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkins Janet Jill

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		17,109	D	$5.42(2)	252,685	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.42 to $5.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Conor Kilroy, as Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aura Biosciences (AURA) disclose in this Form 4 filing?

The filing shows that Aura Biosciences’ Chief Medical Officer sold 17,109 shares of common stock on 11/17/2025 in a transaction related to tax withholding on vested restricted stock units.

How many Aura Biosciences (AURA) shares were sold and at what price?

The officer sold 17,109 shares of Aura Biosciences common stock at a weighted average price of $5.42 per share, with sale prices ranging from $5.42 to $5.44.

Why did the Aura Biosciences officer sell shares in this Form 4?

The filing states that the sales represent shares sold to cover tax withholding obligations resulting from the vesting of restricted stock units, and were executed automatically rather than at the officer’s discretion.

How many Aura Biosciences (AURA) shares does the reporting person own after the transaction?

Following the reported sale, the reporting person beneficially owned 252,685 shares of Aura Biosciences common stock in direct ownership.

Who is the reporting person in this Aura Biosciences Form 4 filing?

The reporting person is an officer of Aura Biosciences, serving as the company’s Chief Medical Officer, as indicated in the relationship section of the filing.

Were the share sale prices detailed in the Aura Biosciences Form 4?

Yes. The filing notes that the reported price is a weighted average of $5.42, with shares sold in multiple transactions at prices ranging from $5.42 to $5.44. The reporting person undertakes to provide full pricing details upon request.